Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors

The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahip...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology, biochemistry and behavior biochemistry and behavior, 1998-08, Vol.60 (4), p.879-887
Hauptverfasser: Bitran, Daniel, Shiekh, Michael, Dowd, Jennifer A., Dugan, Matthew M., Renda, Phyllis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 887
container_issue 4
container_start_page 879
container_title Pharmacology, biochemistry and behavior
container_volume 60
creator Bitran, Daniel
Shiekh, Michael
Dowd, Jennifer A.
Dugan, Matthew M.
Renda, Phyllis
description The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.
doi_str_mv 10.1016/S0091-3057(98)00071-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80060661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305798000719</els_id><sourcerecordid>80060661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-46f5319bf912a472535849c0deb05d331c646371da7e9a3ea233166ef58f9b233</originalsourceid><addsrcrecordid>eNqFkcFvFCEYxYnR1G31T2jCwZj2MArDDAwnUzetbVKjaeuZsMxHis4MIx_btCf_denuZq89EXi_xwfvEXLM2SfOuPx8y5jmlWCtOtHdKWNM8Uq_IgveKVG1XKnXZLFH3pJDxN8FamqpDsiBVkVS9YL8W8aUg4uYIcUJ6BXSn5DGgBgegOZI8z3Qs-kxxOGpcPTce3CZ3t3bTG8A10NGepHiuOG-DtH9sT3Q6OllmOfo7DjbgX4PEyRbxO2s0BergznHhO_IG28HhPe79Yj8uji_W15W1z--XS3PrivX1CxXjfSt4HrlNa9to-pWtF2jHethxdpeCO5kI4XivVWgrQBblzMpwbed16uyOSIft_fOKf5dA2ZT_uhgGOwEcY2mY0wyKfmLIFcNb0qiBWy3oEsRMYE3cwqjTU-GM_PckNk0ZJ7jN7ozm4aMLr7j3YD1aoR-79pVUvQPO92is4NPdnIB91gtOl64gn3ZYlBSewiQDLoAk4M-pNKQ6WN44SH_Aa3_rcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17414057</pqid></control><display><type>article</type><title>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</title><source>ScienceDirect</source><source>MEDLINE</source><creator>Bitran, Daniel ; Shiekh, Michael ; Dowd, Jennifer A. ; Dugan, Matthew M. ; Renda, Phyllis</creator><creatorcontrib>Bitran, Daniel ; Shiekh, Michael ; Dowd, Jennifer A. ; Dugan, Matthew M. ; Renda, Phyllis</creatorcontrib><description>The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/S0091-3057(98)00071-9</identifier><identifier>PMID: 9700972</identifier><identifier>CODEN: PBBHAU</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adrenalectomy ; Adult and adolescent clinical studies ; Animals ; Anti-Anxiety Agents - pharmacology ; Anti-Inflammatory Agents - pharmacology ; Anxiety - psychology ; Anxiety disorders. Neuroses ; Biological and medical sciences ; Corticosterone - pharmacology ; Cortisone - blood ; Defensive burying ; Dexamethasone - pharmacology ; Elevated plus-maze ; Hippocampus - drug effects ; Hippocampus - metabolism ; Male ; Medical sciences ; Microinjections ; Mifepristone - pharmacology ; Mineralocorticoid Receptor Antagonists - pharmacology ; Miscellaneous ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Rats ; Receptors, Glucocorticoid - antagonists &amp; inhibitors ; RU 28318 ; RU 38486 ; Spironolactone - administration &amp; dosage ; Spironolactone - analogs &amp; derivatives ; Spironolactone - pharmacology ; Thigmotaxis</subject><ispartof>Pharmacology, biochemistry and behavior, 1998-08, Vol.60 (4), p.879-887</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-46f5319bf912a472535849c0deb05d331c646371da7e9a3ea233166ef58f9b233</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0091-3057(98)00071-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2381097$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9700972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bitran, Daniel</creatorcontrib><creatorcontrib>Shiekh, Michael</creatorcontrib><creatorcontrib>Dowd, Jennifer A.</creatorcontrib><creatorcontrib>Dugan, Matthew M.</creatorcontrib><creatorcontrib>Renda, Phyllis</creatorcontrib><title>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.</description><subject>Adrenalectomy</subject><subject>Adult and adolescent clinical studies</subject><subject>Animals</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anxiety - psychology</subject><subject>Anxiety disorders. Neuroses</subject><subject>Biological and medical sciences</subject><subject>Corticosterone - pharmacology</subject><subject>Cortisone - blood</subject><subject>Defensive burying</subject><subject>Dexamethasone - pharmacology</subject><subject>Elevated plus-maze</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microinjections</subject><subject>Mifepristone - pharmacology</subject><subject>Mineralocorticoid Receptor Antagonists - pharmacology</subject><subject>Miscellaneous</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Rats</subject><subject>Receptors, Glucocorticoid - antagonists &amp; inhibitors</subject><subject>RU 28318</subject><subject>RU 38486</subject><subject>Spironolactone - administration &amp; dosage</subject><subject>Spironolactone - analogs &amp; derivatives</subject><subject>Spironolactone - pharmacology</subject><subject>Thigmotaxis</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFvFCEYxYnR1G31T2jCwZj2MArDDAwnUzetbVKjaeuZsMxHis4MIx_btCf_denuZq89EXi_xwfvEXLM2SfOuPx8y5jmlWCtOtHdKWNM8Uq_IgveKVG1XKnXZLFH3pJDxN8FamqpDsiBVkVS9YL8W8aUg4uYIcUJ6BXSn5DGgBgegOZI8z3Qs-kxxOGpcPTce3CZ3t3bTG8A10NGepHiuOG-DtH9sT3Q6OllmOfo7DjbgX4PEyRbxO2s0BergznHhO_IG28HhPe79Yj8uji_W15W1z--XS3PrivX1CxXjfSt4HrlNa9to-pWtF2jHethxdpeCO5kI4XivVWgrQBblzMpwbed16uyOSIft_fOKf5dA2ZT_uhgGOwEcY2mY0wyKfmLIFcNb0qiBWy3oEsRMYE3cwqjTU-GM_PckNk0ZJ7jN7ozm4aMLr7j3YD1aoR-79pVUvQPO92is4NPdnIB91gtOl64gn3ZYlBSewiQDLoAk4M-pNKQ6WN44SH_Aa3_rcc</recordid><startdate>19980801</startdate><enddate>19980801</enddate><creator>Bitran, Daniel</creator><creator>Shiekh, Michael</creator><creator>Dowd, Jennifer A.</creator><creator>Dugan, Matthew M.</creator><creator>Renda, Phyllis</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7X8</scope></search><sort><creationdate>19980801</creationdate><title>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</title><author>Bitran, Daniel ; Shiekh, Michael ; Dowd, Jennifer A. ; Dugan, Matthew M. ; Renda, Phyllis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-46f5319bf912a472535849c0deb05d331c646371da7e9a3ea233166ef58f9b233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adrenalectomy</topic><topic>Adult and adolescent clinical studies</topic><topic>Animals</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anxiety - psychology</topic><topic>Anxiety disorders. Neuroses</topic><topic>Biological and medical sciences</topic><topic>Corticosterone - pharmacology</topic><topic>Cortisone - blood</topic><topic>Defensive burying</topic><topic>Dexamethasone - pharmacology</topic><topic>Elevated plus-maze</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microinjections</topic><topic>Mifepristone - pharmacology</topic><topic>Mineralocorticoid Receptor Antagonists - pharmacology</topic><topic>Miscellaneous</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Rats</topic><topic>Receptors, Glucocorticoid - antagonists &amp; inhibitors</topic><topic>RU 28318</topic><topic>RU 38486</topic><topic>Spironolactone - administration &amp; dosage</topic><topic>Spironolactone - analogs &amp; derivatives</topic><topic>Spironolactone - pharmacology</topic><topic>Thigmotaxis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bitran, Daniel</creatorcontrib><creatorcontrib>Shiekh, Michael</creatorcontrib><creatorcontrib>Dowd, Jennifer A.</creatorcontrib><creatorcontrib>Dugan, Matthew M.</creatorcontrib><creatorcontrib>Renda, Phyllis</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bitran, Daniel</au><au>Shiekh, Michael</au><au>Dowd, Jennifer A.</au><au>Dugan, Matthew M.</au><au>Renda, Phyllis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>1998-08-01</date><risdate>1998</risdate><volume>60</volume><issue>4</issue><spage>879</spage><epage>887</epage><pages>879-887</pages><issn>0091-3057</issn><eissn>1873-5177</eissn><coden>PBBHAU</coden><abstract>The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9700972</pmid><doi>10.1016/S0091-3057(98)00071-9</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-3057
ispartof Pharmacology, biochemistry and behavior, 1998-08, Vol.60 (4), p.879-887
issn 0091-3057
1873-5177
language eng
recordid cdi_proquest_miscellaneous_80060661
source ScienceDirect; MEDLINE
subjects Adrenalectomy
Adult and adolescent clinical studies
Animals
Anti-Anxiety Agents - pharmacology
Anti-Inflammatory Agents - pharmacology
Anxiety - psychology
Anxiety disorders. Neuroses
Biological and medical sciences
Corticosterone - pharmacology
Cortisone - blood
Defensive burying
Dexamethasone - pharmacology
Elevated plus-maze
Hippocampus - drug effects
Hippocampus - metabolism
Male
Medical sciences
Microinjections
Mifepristone - pharmacology
Mineralocorticoid Receptor Antagonists - pharmacology
Miscellaneous
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Rats
Receptors, Glucocorticoid - antagonists & inhibitors
RU 28318
RU 38486
Spironolactone - administration & dosage
Spironolactone - analogs & derivatives
Spironolactone - pharmacology
Thigmotaxis
title Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A42%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Corticosterone%20Is%20Permissive%20to%20the%20Anxiolytic%20Effect%20That%20Results%20From%20the%20Blockade%20of%20Hippocampal%20Mineralocorticoid%20Receptors&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Bitran,%20Daniel&rft.date=1998-08-01&rft.volume=60&rft.issue=4&rft.spage=879&rft.epage=887&rft.pages=879-887&rft.issn=0091-3057&rft.eissn=1873-5177&rft.coden=PBBHAU&rft_id=info:doi/10.1016/S0091-3057(98)00071-9&rft_dat=%3Cproquest_cross%3E80060661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17414057&rft_id=info:pmid/9700972&rft_els_id=S0091305798000719&rfr_iscdi=true